August 18, 2016

Symphogen’s founding CEO Kirsten Drejer steps down and becomes Executive Director

Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today that Kirsten Drejer, M.Sc., Ph. D., Co-founder, Chief Executive Officer and Director will transition from an executive operational role to an independent member of the Board of Directors. In parallel, Martin Olin, M.Sc., E*MBA, now Chief Financial Officer, has been promoted effective 1st September to Chief Executive Officer and member of the Board of Directors. Kirsten Drejer is proposed to be elected to the Board of Directors as an independent member and will, through a transition period, be a working Board member assisting Martin Olin.
Read more
May 11, 2016

Symphogen announces the appointment of Jeffrey H. Buchalter and Christoffer Søderberg as Non-Executive Directors

Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today the appointment to the company's Board of Directors two new Non-Executive Directors: Mr. Jeffrey H. Buchalter and Mr. Christoffer Søderberg, effective 10 May 2016.

Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today the appointment to the company's Board of Directors two new Non-Executive Directors: Mr. Jeffrey H. Buchalter and Mr. Christoffer Søderberg, effective 10 May 2016.
Read more
April 12, 2016

Symphogen Initiates Anti-MET Clinical Program And Presents Pre-Clinical Anti-MET Data at Annual AACR Meeting April 18th in New Orleans

Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today dosing of the first patient in its Sym015 program. Sym015 is an investigational mixture of two antibodies, targeting the MET receptor. The Phase 1 dose escalation study in patients with solid tumors will be followed by an expansion cohort in a subset patient population with a pre-identified gene signature. Two sites, START of San Antonio, Texas and The University of Texas MD Anderson Cancer Centre of Houston, Texas, will conduct the first-in-human study. Kirsten Drejer, Ph.D., Chief Executive Officer, said, "The initiation of this Phase 1 study represents a significant achievement by Symphogen in moving this promising program forward. It is our second proprietary clinical program, using antibody mixture targeting receptor tyrosine kinase, bringing Symphogen's total number of ongoing clinical studies to four. Importantly, we have retained all rights to the program." Anthony Tolcher, MD, FRCPC, FACP, President and co-founder of START, said, "We are enthusiastic about bringing this unique approach of an antibody mixture into the clinic. MET is a very exciting target for several solid tumors, and may have potential across multiple other tumor types. As such, Symphogen's novel antibody mixture may provide a unique opportunity to improve the life of patients with limited therapeutic options."
Read more
January 12, 2016

Symphogen to Present at JPMorgan Conference in San Francisco, CA

Symphogen, a private biopharmaceutical Company developing recombinant antibody mixtures, announced today that Kirsten Drejer, Chief Executive Officer, will present an update on the Company at the 34th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2016 from 11:00 AM - 11.25 AM at San Francisco's Westin St. Francis Hotel in the Elizabethan D meeting room. The company announced earlier this month a strategic collaboration with Baxalta Incorporated, worth up to $1.6 billion plus royalties, to develop immuno-oncology candidate products.
Read more
January 4, 2016

Baxalta and Symphogen Establish Strategic Collaboration to Accelerate Innovation in Immuno-Oncology

Partnership aims to advance development of novel immune checkpoint therapies as Baxalta expands oncology leadership in orphan diseases. Symphogen to receive $175 million (€160 million) upfront, in addition to potential future milestone payments and royalties.
Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, and Symphogen, a private biopharmaceutical company developing recombinant antibodies and antibody mixtures, today announced a broad strategic immuno-oncology collaboration.
Read more
December 2, 2015

Symphogen Receives Milestone Payment from Genentech for Initiation of Phase 1 Clinical Trial Candidate

Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today that Genentech, a member of the Roche Group, has dosed for the first time in humans a clinical trial candidate containing a Symplex generated antibody conjugated to an undisclosed active agent.
Read more
October 22, 2015

Symphogen Announces Closing of a EUR 67.5 M Financing Subscribed by Existing Investors

Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today the closing of a EUR 67.5 million convertible debt facility, secured from existing investors, led by Novo A/S and the Danish pension fund PKA. The proceeds will be used to progress the company's pipeline, specifically Sym004, a novel antibody mixture and its lead clinical program currently in a multi-center Phase 2b study in metastatic colorectal cancer patients with disease resistance or refractory to anti-EGFR antibody therapies. In addition, funds are earmarked to advance to the clinic both of the company's other fully owned assets, the pan-HER product candidate, Sym013, a mixture of six antibodies targeting each of EGFR, HER2 and HER3 and its MET product candidate, Sym015, a mixture of two antibodies targeting the MET receptor for treatment of patients with MET-amplified tumors. Symphogen is also deploying its proprietary mAb mix approach to its immuno-oncology research programs.

The closing of the convertible loan facility brings Symphogen's total pro-forma cash resources to a total of EUR 110 million.
Read more
January 29, 2015

Symphogen Regains Rights to Sym004 Announces Organizational Changes

Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today several new corporate initiatives that reposition the company to focus on its proprietary pipeline of clinical oncology programs. The announcements address the regained rights to Sym004, a novel antibody mixture currently in a Phase 2b program, and a prioritization of the company's discovery activities in immuno-oncology.
Read more
Read more about our ownership